Roche and Bayer are expanding their companion Dx collaboration; Quest Diagnostics snatched up Summit Health;

> Roche ($RHHBY) and Bayer have expanded their companion diagnostics collaboration into multiple projects. Story

> Harvard Medical School and Columbia University won grants of about $12.3 million this year from the National Institute of Allergy and Infectious Diseases to develop translational research centers focused on molecular diagnostics technologies. Story (reg. req)

> Exosome Diagnostics raised a $27 million Series B round, led by Qiagen ($QGEN) and Arcus Ventures, to help propel its prostate cancer urine test to market. Story

> Seattle's Pacific Biomarkers will use its biomarker assays in a collaboration deal with Shanghai's WuXi PharmaTech ($WX) focused on the development of new treatments. Release

> Quest Diagnostics ($DGX) said it will buy Summit Health, an Arizona company that provides finger-stick diagnostics and other biometric screenings. Financial terms were not disclosed. Release

> NeuroMetrix ($NURO) plans to seek regulatory approval in Japan for its point-of-care test to detect diabetic peripheral neuropathy. Release

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.